ArticleCancer medicine2022

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.

Yuichiro Doki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.